{"title":"家禽用重组病毒疫苗的现状和未来。","authors":"M W Jackwood","doi":"10.1016/s0065-3519(99)80038-x","DOIUrl":null,"url":null,"abstract":"<p><p>The use of biotechnology to create recombinant viral vaccines holds many promises for the future. But, to be practical, new vaccines must have a selective advantage over traditional vaccines. A vaccine that is novel because it is a recombinant vaccine is not enough. Recombinant vaccines must be safer, or more efficacious, or less expensive to produce in order for them to gain a niche in the marketplace.</p>","PeriodicalId":72111,"journal":{"name":"Advances in veterinary medicine","volume":"41 ","pages":"517-22"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0065-3519(99)80038-x","citationCount":"19","resultStr":"{\"title\":\"Current and future recombinant viral vaccines for poultry.\",\"authors\":\"M W Jackwood\",\"doi\":\"10.1016/s0065-3519(99)80038-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The use of biotechnology to create recombinant viral vaccines holds many promises for the future. But, to be practical, new vaccines must have a selective advantage over traditional vaccines. A vaccine that is novel because it is a recombinant vaccine is not enough. Recombinant vaccines must be safer, or more efficacious, or less expensive to produce in order for them to gain a niche in the marketplace.</p>\",\"PeriodicalId\":72111,\"journal\":{\"name\":\"Advances in veterinary medicine\",\"volume\":\"41 \",\"pages\":\"517-22\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/s0065-3519(99)80038-x\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in veterinary medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s0065-3519(99)80038-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in veterinary medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0065-3519(99)80038-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Current and future recombinant viral vaccines for poultry.
The use of biotechnology to create recombinant viral vaccines holds many promises for the future. But, to be practical, new vaccines must have a selective advantage over traditional vaccines. A vaccine that is novel because it is a recombinant vaccine is not enough. Recombinant vaccines must be safer, or more efficacious, or less expensive to produce in order for them to gain a niche in the marketplace.